Showing results (41-50 of 53) with videos related to
Sort By:
Pageof 6
Cell Host & Microbe|October 31, 2024
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patientsAngeli D G Macandog, Carlotta Catozzi, Mariaelena Capone, et al.Cell Research|September 5, 2019
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockadeNicolas Jacquelot, Takahiro Yamazaki, Maria P Roberti, et al.Oncoimmunology|November 15, 2021
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanomaMichael G White, Robert Szczepaniak Sloane, Russell G Witt, et al.Nature Communications|April 17, 2020
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanomaAkash Mitra, Miles C Andrews, Whijae Roh, et al.Nature Communications|July 9, 2022
Multi-modal molecular programs regulate melanoma cell stateMiles C Andrews, Junna Oba, Chang-Jiun Wu, et al.The Lancet. Oncology|January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trialRodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.Nature Medicine|October 27, 2018
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.Nature Medicine|October 10, 2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.Nature Medicine|October 27, 2018
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.Nature|June 15, 2022
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapyChristopher P Vellano, Michael G White, Miles C Andrews, et al.Pageof 6